Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00621673 · ClinicalTrials.gov registry record · Phase 4
Assessment of the Risk of Inhibitor Formation in Previously Treated Patients With Severe Hemophilia A
A Phase 4 study, sponsored by Bayer.
- Terminated
- Registry status
- Phase 4
- Development phase
- 1
- Enrollment target
NCT00621673: Clinical Trial Phase 4 study, sponsored by Bayer.
NCT00621673 is a Phase 4 study that was terminated before completion, run by Bayer. The registered enrollment target is 1 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00621673, a Phase 4 study, was terminated before completion, sponsored by Bayer.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 1 participants
- Enrollment target
Study Summary
Most transient inhibitor formation, if any, will develop within the first 4 weeks. The study is to further monitor whether participants with severe Hemophilia A will develop inhibitors or antibodies at the later stage when switched from their current recombinant therapy produced from Chinese Hamster Ovary (CHO) cell line to Kogenate-FS raised in a Baby Hamster Kidney cell line.
Interventions
- DRUG Kogenate (BAY 14-2222)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2006-05 |
| Est. Completion | 2006-10 |
| Phase | Phase 4 |
Why NCT00621673 stopped before completion
NCT00621673 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 1 intervention - of which Kogenate (BAY 14-2222) is the first listed.
NCT00621673 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00621673 about?
NCT00621673 is a clinical study titled "Assessment of the Risk of Inhibitor Formation in Previously Treated Patients With Severe Hemophilia A". Most transient inhibitor formation, if any, will develop within the first 4 weeks. The study is to further monitor whether participants with severe Hemophilia A will develop inhibitors or antibodies at the later stage when switched from their current recombinant therapy produced from Chinese Hamster...
What is the current status of trial NCT00621673?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 1 participants. The study started on 2006-05. Estimated completion is 2006-10.
What interventions are being tested in trial NCT00621673?
The interventions under investigation include: Kogenate (BAY 14-2222) (DRUG).
Who is sponsoring clinical trial NCT00621673?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00621673's enrollment target sits among peer trials
1 2000th of 2000 the lowest of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia